PDL BioPharma, Inc. (NASDAQ: PDLI) is a biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life- threatening illnesses. Commercially focused in the acute-care hospital setting, PDL markets and sells its portfolio of leading products in the United States and Canada. A pioneer of antibody humanization technology, PDL promotes this technology through licensing agreements and clinical development of its own diverse pipeline of investigational compounds. PDL’s research platform centers on the discovery and development of antibodies to treat cancer and autoimmune diseases. For more information, please visit www.pdl.com.
People
Patrick Caldwell (VP Finance/Controller)
Karen Dawes (Board Member)
Stanley Falkow (Board Member)
Andrew Guggenhime (CFO)
Barbara Finck (VP Clinical Development)
News
Life-science briefing: Monday, March 10, 2008
March 10, 2008 1:00 pm
TODAY’S HEADLINES: BrainCells raises $30M for neuroregeneration drugs (release) EKR Therapeutics takes in $50M plus $95M in debt for pain,… Continue reading ⟩
EKR Therapeutics and the sweet taste of "re-acquisition"
February 6, 2008 9:19 pm
A few months ago, I wrote about the intriguing trend toward “re-launching” biotech startups that had been recently acquired by… Continue reading ⟩
Life sciences briefing: Wednesday, Feb. 6, 2008
February 6, 2008 10:52 am
TODAY’S HEADLINES: H-P “great-grandchild” Alverix raises $7.7M for portable diagnostic devices (release) Moksha8 takes in $39M to commercialize drugs for… Continue reading ⟩